IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
InflaRx N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$1.45+0.13 (+9.85%)
Close on Oct 19, 2026
Ownership
Who owns InflaRx's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alex Silverstein | 8,911,348 | 6.10% | 13G (passive) | Jun 30, 2026 |
| FMR LLC | 8,163,341 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Suvretta Capital Management, LLC | 7,933,910 | 11.70% | 13G (passive) amendment | Dec 31, 2025 |
| Wehrly, Mark C. | 7,500,000 | 5.10% | 13G (passive) | May 7, 2026 |
| Commodore Capital LP | 7,475,000 | 5.10% | 13G (passive) | Aug 10, 2026 |
| Montanova Capital, LLC | 22,933,910 | 15.60% | 13G (passive) amendment | Jun 30, 2026 |
| TCG Crossover GP III, LLC | 14,500,000 | 9.80% | 13G (passive) | May 7, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Renfeng Guo | Chief Scientific Officer, Director | 1,762,144 | 2.44% | Mar 18, 2026 |
| Niels Riedemann | Chief Executive Officer, Director | 1,068,908 | 1.48% | Mar 18, 2026 |
| Thomas Taapken | Chief Financial Officer | 3,500 | 0.00% | Mar 18, 2026 |
| Derval OCarroll | See Remarks | – | – | Mar 18, 2026 |
| Mark Kubler | Director | 960,015 | 1.33% | Mar 18, 2026 |
| Nicolas Fulpius | Director | 490,052 | 0.68% | Mar 18, 2026 |
| Hege Hellstrom | Director | – | – | Mar 18, 2026 |
| Anthony S. Gibney | Director | 10,000 | 0.01% | Mar 18, 2026 |
| Richard Brudnick | Director | 50,000 | 0.07% | Mar 18, 2026 |